Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 7.01 (Regulation FD Disclosure). $20 million development milestone payable to Keros following first-patient dosing in elritercept’s ELRiSE MF trial.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- $20 million development milestone payable to Keros following first-patient dosing in elritercept’s ELRiSE MF trial
- ELRiSE MF advancement into Phase 3 supports elritercept’s progression toward potential myelofibrosis approval
- Trial evaluates elritercept versus placebo in patients with myelofibrosis and anemia receiving concurrent ruxolitinib
- Payment under Takeda license agreement provides non-dilutive funding and validates partner commitment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.